Daxor Corporation (NASDAQ:DXR) Short Interest Update
Daxor Corporation (NASDAQ:DXR - Get Free Report) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 348 shares, a decline of 76. 4% from the July 15th total of 1,472 shares. Based on an average trading volume of 1,908 shares, the days-to-cover ratio is presently 0. 2 days. Currently, 0. 0% of the shares of the company are sold short.
Daxor Corporation (NASDAQ:DXR-Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 348 shares, a decrease of 76. 4% from the July 15th total of 1,472 shares. Approximately 0. 0% of the company's shares are sold short. Based on an average daily trading volume, of 1,908 shares, the short-interest ratio is presently 0. 2 days. GetDaxoralerts:Daxor Stock Up 2. 5%NASDAQ:DXRtraded up $0. 25 during mid-day trading on Thursday, reaching $10. 45. The company's stock had a trading volume of 527 shares, compared to its average volume of 7,061. The company's fifty day simple moving average is $10. 36 and its two-hundred day simple moving average is $10. 76. Daxor has a twelve month low of $8. 56 and a twelve month high of $14. 76. Analyst Upgrades and DowngradesSeparately,Weiss Ratingsreiterated a "hold (c)" rating on shares of Daxor in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat. com, the stock presently has a consensus rating of "Moderate Buy". Read Our Latest Stock Analysis on DaxorInstitutional Trading of DaxorInstitutional investors have recently made changes to their positions in the stock. Aristides Capital LLC purchased a new stake in shares of Daxor during the 1st quarter valued at about $403,000. Empirical Financial Services LLC d. b. a. Empirical Wealth Management acquired a new position in Daxor during the 1st quarter worth $245,000. Osaic Holdings Inc. acquired a new position in Daxor during the 2nd quarter worth $86,000. Crescent Grove Advisors LLC bought a new stake in shares of Daxor in the 1st quarter worth about $104,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Daxor in the 4th quarter valued at about $184,000. 1. 34% of the stock is owned by hedge funds and other institutional investors. About Daxor(Get Free Report)Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company's core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient's fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload. In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting. Featured StoriesFive stocks we like better than DaxorAsian Market Circuit Breakers Hit Stocks, Not AI DemandRiot Platforms Re-Wires the Ledger for a $9B AI Power PlayNebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Joby’s Defense Pivot Accelerates With $500M Resonant Sciences DealThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat. com. Continue following MarketBeatAdd MarketBeat as your preferred source on Google to see our latest stories in your feed. Should You Invest $1,000 in Daxor Right Now?Before you consider Daxor, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified thefive stocksthat top analysts are quietly whispering to their clients to buy now before the broader market catches on. . . and Daxor wasn't on the list. While Daxor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks HereMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely. Get This Free Report